These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22054289)

  • 1. Effect of homoharringtonine on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia.
    Li YF; Deng Z; Din BH; Zhu JB
    Leuk Lymphoma; 2012 May; 53(5):934-9. PubMed ID: 22054289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
    Li Y; Deng Z; Zho J; Ding B; Shi Y; Li Y
    Acta Haematol; 2014; 132(2):172-6. PubMed ID: 24603361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
    Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
    Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.
    O'Brien S; Kantarjian H; Keating M; Beran M; Koller C; Robertson LE; Hester J; Rios MB; Andreeff M; Talpaz M
    Blood; 1995 Nov; 86(9):3322-6. PubMed ID: 7579434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
    Wang Q; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
    Visani G; Russo D; Ottaviani E; Tosi P; Damiani D; Michelutti A; Manfroi S; Baccarani M; Tura S
    Leukemia; 1997 May; 11(5):624-8. PubMed ID: 9180282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
    Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
    Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
    O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios MB; Talpaz M
    Blood; 1999 Jun; 93(12):4149-53. PubMed ID: 10361112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
    Dybko J; Haus O; Jazwiec B; Urbaniak J; Wozniak M; Kaczmar-Dybko A; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
    Acta Haematol; 2014; 132(2):166-71. PubMed ID: 24577437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
    Li YF; Liu X; Liu DS; Din BH; Zhu JB
    Leuk Lymphoma; 2009 Nov; 50(11):1889-91. PubMed ID: 19860613
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunological status of chronic myelogenous leukemia patients with complete cytogenetic response after treatment.
    Deng Z; Li Y; Li YF
    Tumori; 2015; 101(3):323-7. PubMed ID: 26045111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
    Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
    Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.
    Zhou M; Zeng J; Wang X; Guo Q; Huang T; Shen H; Fu Y; Wang L; Jia J; Chen C
    J Transl Med; 2013 Oct; 11():265. PubMed ID: 24148180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
    Lü S; Wang J
    J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
    Fang B; Li N; Song Y; Han Q; Zhao RC
    Ann Hematol; 2010 Nov; 89(11):1099-105. PubMed ID: 20499235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homoharringtonine for the treatment of chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative proteomic study of Homoharringtonine-induced apoptosis in leukemia K562 cells.
    Zhou X; Xu N; Li R; Xiao Y; Gao G; Lu Q; Ding L; Li L; Li Y; Du Q; Liu X
    Leuk Lymphoma; 2015 Jul; 56(7):2162-9. PubMed ID: 25330443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of interferon-α combined with homoharringtonine on chronic myelogenous leukemia in chronic phase.
    Zhu J; Ding B; Li Y
    Leuk Lymphoma; 2013 Jul; 54(7):1426-9. PubMed ID: 23270584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.